Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT

Johannes Kopf-Beck, Petra Zimmermann, Samy Egli, Martin Rein, Nils Kappelmann, Julia Fietz, Jeanette Tamm, Katharina Rek, Susanne Lucae, Anna-Katharine Brem, Philipp Sämann, Leonhard Schilbach, Martin E Keck, Johannes Kopf-Beck, Petra Zimmermann, Samy Egli, Martin Rein, Nils Kappelmann, Julia Fietz, Jeanette Tamm, Katharina Rek, Susanne Lucae, Anna-Katharine Brem, Philipp Sämann, Leonhard Schilbach, Martin E Keck

Abstract

Background: Major depressive disorder represents (MDD) a major cause of disability and disease burden. Beside antidepressant medication, psychotherapy is a key approach of treatment. Schema therapy has been shown to be effective in the treatment of psychiatric disorders, especially personality disorders, in a variety of settings and patient groups. Nevertheless, there is no evidence on its effectiveness for MDD in an inpatient nor day clinic setting and little is known about the factors that drive treatment response in such a target group.

Methods: In the current protocol, we outline OPTIMA (OPtimized Treatment Identification at the MAx Planck Institute): a single-center randomized controlled trial of schema therapy as a treatment approach for MDD in an inpatient and day clinic setting. Over the course of 7 weeks, we compare schema therapy with cognitive behavioral therapy and individual supportive therapy, conducted in individual and group sessions and with no restrictions regarding concurrent antidepressant medication, thus approximating real-life treatment conditions. N = 300 depressed patients are included. All study therapists undergo a specific training and supervision and therapy adherence is assessed. Primary outcome is depressive symptom severity as self-assessment (Beck Depression Inventory-II) and secondary outcomes are clinical ratings of MDD (Montgomery-Asberg Depression Rating Scale), recovery rates after 7 weeks according to the Munich-Composite International Diagnostic Interview, general psychopathology (Brief Symptom Inventory), global functioning (World Health Organization Disability Assessment Schedule), and clinical parameters such as dropout rates. Further parameters on a behavioral, cognitive, psychophysiological, and biological level are measured before, during and after treatment and in 2 follow-up assessments after 6 and 24 months after end of treatment.

Discussion: To our knowledge, the OPTIMA-Trial is the first to investigate the effectiveness of schema therapy as a treatment approach of MDD, to investigate mechanisms of change, and explore predictors of treatment response in an inpatient and day clinic setting by using such a wide range of parameters. Insights from OPTIMA will allow more integrative approaches of psychotherapy of MDD. Especially, the identification of intervention-specific markers of treatment response can improve evidence-based clinical decision for individualizing treatment.

Trial registration: Identifier on clinicaltrials.gov : NCT03287362 ; September, 12, 2017.

Keywords: Cognitive behavioral therapy; Depression; Mechanisms of change; Personalized psychiatry; Psychotherapy; Randomized controlled trial; Relapse prevention; Schema therapy; Supportive therapy; Treatment prediction.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of enrollment and assessments of the OPTIMA-Study. Note: *Assessment domains are obligatory for participation. EMA – Ecological Momentary Assessment

References

    1. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7.
    1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–138. doi: 10.1146/annurev-publhealth-031912-114409.
    1. Üstün TB, Ayuso-Mateos JL, Chattereji S, Mathers C, Murray CJL. Global burden of depressive disorders in the year. Br J Psychiatry. 2000;2004:386–392.
    1. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–1366. doi: 10.1016/S0140-6736(17)32802-7.
    1. Barth J, Munder T, Gerger H, Nüesch E, Trelle S, Znoj H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med. 2013;10:e1001454. doi: 10.1371/journal.pmed.1001454.
    1. Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Huibers MJH. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry. 2016;15:245–258. doi: 10.1002/wps.20346.
    1. Hollon SD, Thase ME, Markowitz JC. Treatment and prevention of depression. Psychol Sci Public Interest. 2002;3(2):39–77.
    1. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013;12:137–148. doi: 10.1002/wps.20038.
    1. Kolovos S, van Tulder MW, Cuijpers P, Prigent A, Chevreul K, Riper H, et al. The effect of treatment as usual on major depressive disorder: a meta-analysis. J Affect Disord. 2017;210:72–81. doi: 10.1016/j.jad.2016.12.013.
    1. Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol. 2007;75:475–488. doi: 10.1037/0022-006X.75.3.475.
    1. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23:335–343. doi: 10.1038/mp.2016.167.
    1. Köhler-Forsberg O, N Lydholm C, Hjorthøj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139:404–419. doi: 10.1111/acps.13016.
    1. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse. 5 2002.
    1. McCullough JP. Treatment for chronic depression: cognitive behavioral analysis system of psychotherapy (CBASP) New York, London: Guilford; 2004.
    1. Young JE, Klosko JS, Weishaar ME. Schema therapy: a practitioner's guide. New York, London: Guilford; 2007.
    1. Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord. 2015;172:96–102. doi: 10.1016/j.jad.2014.10.010.
    1. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its Specifiers in the United States. JAMA Psychiat. 2018;75:336–346. doi: 10.1001/jamapsychiatry.2017.4602.
    1. Asp M, Lindqvist D, Fernström J, Ambrus L, Tuninger E, Reis M, et al. Recognition of personality disorder and anxiety disorder comorbidity in patients treated for depression in secondary psychiatric care. PLoS One. 2020;15:e0227364. doi: 10.1371/journal.pone.0227364.
    1. Hirschfeld RMA. Personality disorders and depression: comorbidity. Depress Anxiety. 1999;10:142–146. doi: 10.1002/(SICI)1520-6394(1999)10:4<142::AID-DA2>;2-Q.
    1. Zimmerman M, Chelminski I, Young D. The frequency of personality disorders in psychiatric patients. Psychiatr Clin North Am. 2008;31:405–420. doi: 10.1016/j.psc.2008.03.015.
    1. Grilo CM, Sanislow CA, Shea MT, Skodol AE, Stout RL, Gunderson JG, et al. Two-year prospective naturalistic study of remission from major depressive disorder as a function of personality disorder comorbidity. J Consult Clin Psychol. 2005;73:78–85. doi: 10.1037/0022-006X.73.1.78.
    1. Newton-Howes G, Tyrer P, Johnson T, Mulder R, Kool S, Dekker J, et al. Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis. J Pers Disord. 2014;28:577–593. doi: 10.1521/pedi_2013_27_070.
    1. Bamelis LLM, Evers SMAA, Spinhoven P, Arntz A. Results of a multicenter randomized controlled trial of the clinical effectiveness of schema therapy for personality disorders. Am J Psychiatry. 2014;171:305–322. doi: 10.1176/appi.ajp.2013.12040518.
    1. Carter JD, McIntosh VV, Jordan J, Porter RJ, Frampton CM, Joyce PR. Psychotherapy for depression: a randomized clinical trial comparing schema therapy and cognitive behavior therapy. J Affect Disord. 2013;151:500–505. doi: 10.1016/j.jad.2013.06.034.
    1. Malogiannis IA, Arntz A, Spyropoulou A, Tsartsara E, Aggeli A, Karveli S, et al. Schema therapy for patients with chronic depression: a single case series study. J Behav Ther Exp Psychiatry. 2014;45:319–329. doi: 10.1016/j.jbtep.2014.02.003.
    1. Renner F, Arntz A, Peeters FPML, Lobbestael J, Huibers MJH. Schema therapy for chronic depression: results of a multiple single case series. J Behav Ther Exp Psychiatry. 2016;51:66–73. doi: 10.1016/j.jbtep.2015.12.001.
    1. Kellogg SH, Young JE. Schema therapy for borderline personality disorder. J Clin Psychol. 2006;62:445–458. doi: 10.1002/jclp.20240.
    1. Beck AT. Cognitive models of depression. J Cogn Psychother. 1987;1:5–37.
    1. Giesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T, et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry. 2006;63:649–658. doi: 10.1001/archpsyc.63.6.649.
    1. Nordahl HM, Nysaeter TE. Schema therapy for patients with borderline personality disorder: a single case series. J Behav Ther Exp Psychiatry. 2005;36:254–264. doi: 10.1016/j.jbtep.2005.05.007.
    1. Nadort M, van Dyck R, Smit JH, Giesen-Bloo J, Eikelenboom M, Wensing M, et al. Three preparatory studies for promoting implementation of outpatient schema therapy for borderline personality disorder in general mental health care. Behav Res Ther. 2009;47:938–945. doi: 10.1016/j.brat.2009.07.004.
    1. Farrell JM, Shaw IA, Webber MA. A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2009;40:317–328. doi: 10.1016/j.jbtep.2009.01.002.
    1. Sempértegui GA, Karreman A, Arntz A, Bekker MHJ. Schema therapy for borderline personality disorder: a comprehensive review of its empirical foundations, effectiveness and implementation possibilities. Clin Psychol Rev. 2013;33:426–447. doi: 10.1016/j.cpr.2012.11.006.
    1. Nordahl HM, Holthe H, Haugum JA. Early maladaptive schemas in patients with or without personality disorders: does schema modification predict symptomatic relief? Clin Psychol Psychother. 2005;12:142–149. doi: 10.1002/cpp.430.
    1. Baljé A, Greeven A, van Giezen A, Korrelboom K, Arntz A, Spinhoven P. Group schema therapy versus group cognitive behavioral therapy for social anxiety disorder with comorbid avoidant personality disorder: study protocol for a randomized controlled trial. Trials. 2016;17:487. doi: 10.1186/s13063-016-1605-9.
    1. Hoffart Lunding S, Hoffart A. Perceived parental bonding, early maladaptive schemas and outcome in schema therapy of cluster C personality problems. Clin Psychol Psychother. 2016;23:107–117. doi: 10.1002/cpp.1938.
    1. Cockram DM, Drummond PD, Lee CW. Role and treatment of early maladaptive schemas in Vietnam veterans with PTSD. Clin Psychol Psychother. 2010;17:165–182. doi: 10.1002/cpp.690.
    1. Pugh M. A narrative review of schemas and schema therapy outcomes in the eating disorders. Clin Psychol Rev. 2015;39:30–41. doi: 10.1016/j.cpr.2015.04.003.
    1. McIntosh VVW, Jordan J, Carter JD, Frampton CMA, McKenzie JM, Latner JD, et al. Psychotherapy for transdiagnostic binge eating: a randomized controlled trial of cognitive-behavioural therapy, appetite-focused cognitive-behavioural therapy, and schema therapy. Psychiatry Res. 2016;240:412–420. doi: 10.1016/j.psychres.2016.04.080.
    1. Thiel N, Jacob GA, Tuschen-Caffier B, Herbst N, Külz AK, Hertenstein E, et al. Schema therapy augmented exposure and response prevention in patients with obsessive-compulsive disorder: feasibility and efficacy of a pilot study. J Behav Ther Exp Psychiatry. 2016;52:59–67. doi: 10.1016/j.jbtep.2016.03.006.
    1. van Wijk-Herbrink MF, Broers NJ, Roelofs J, Bernstein DP. Schema therapy in adolescents with disruptive behavior disorders. Int J Forensic Ment Health. 2017;16:261–279. doi: 10.1080/14999013.2017.1352053.
    1. Vuijk R, Arntz A. Schema therapy as treatment for adults with autism spectrum disorder and comorbid personality disorder: protocol of a multiple-baseline case series study testing cognitive-behavioral and experiential interventions. Contemp Clin Trials Commun. 2017;5:80–85. doi: 10.1016/j.conctc.2017.01.001.
    1. Dadomo H, Grecucci A, Giardini I, Ugolini E, Carmelita A, Panzeri M. Schema therapy for emotional Dysregulation: theoretical implication and clinical applications. Front Psychol. 2016;7:1987. doi: 10.3389/fpsyg.2016.01987.
    1. Fassbinder E, Schweiger U, Martius D, Brand-de Wilde O, Arntz A. Emotion regulation in schema therapy and dialectical behavior therapy. Front Psychol. 2016;7:1373. doi: 10.3389/fpsyg.2016.01373.
    1. Arntz A, Stupar-Rutenfrans S, Bloo J, van Dyck R, Spinhoven P. Prediction of treatment discontinuation and recovery from borderline personality disorder: results from an RCT comparing schema therapy and transference focused psychotherapy. Behav Res Ther. 2015;74:60–71. doi: 10.1016/j.brat.2015.09.002.
    1. Nenadić I, Lamberth S, Reiss N. Group schema therapy for personality disorders: a pilot study for implementation in acute psychiatric in-patient settings. Psychiatry Res. 2017;253:9–12. doi: 10.1016/j.psychres.2017.01.093.
    1. Schaap GM, Chakhssi F, Westerhof GJ. Inpatient schema therapy for nonresponsive patients with personality pathology: changes in symptomatic distress, schemas, schema modes, coping styles, experienced parenting styles, and mental well-being. Psychotherapy (Chic) 2016;53:402–412. doi: 10.1037/pst0000056.
    1. Videler AC, van Alphen SPJ, van Royen RJJ, van der Feltz-Cornelis CM, Rossi G, Arntz A. Schema therapy for personality disorders in older adults: a multiple-baseline study. Aging Ment Health. 2018;22:738–747. doi: 10.1080/13607863.2017.1318260.
    1. Khasho DA, van Alphen SPJ, Heijnen-Kohl SMJ, Ouwens MA, Arntz A, Videler AC. The effectiveness of individual schema therapy in older adults with borderline personality disorder: protocol of a multiple-baseline study. Contemp Clin Trials Commun. 2019;14:100330. doi: 10.1016/j.conctc.2019.100330.
    1. Bernstein DP, Keulen-de Vos M, Jonkers P, de Jonge E, Arntz A. Schema therapy in forensic settings. In: The Wiley-Blackwell handbook of schema therapy: theory, research, and practice. Chichester: Wiley; 2012.
    1. Fassbinder E, Schuetze M, Kranich A, Sipos V, Hohagen F, Shaw I, et al. Feasibility of group schema therapy for outpatients with severe borderline personality disorder in Germany: a pilot study with three year follow-up. Front Psychol. 2016;7:1851. doi: 10.3389/fpsyg.2016.01851.
    1. Skewes SA, Samson RA, Simpson SG, van Vreeswijk M. Short-term group schema therapy for mixed personality disorders: a pilot study. Front Psychol. 2014;5:1592. doi: 10.3389/fpsyg.2014.01592.
    1. Dickhaut V, Arntz A. Combined group and individual schema therapy for borderline personality disorder: a pilot study. J Behav Ther Exp Psychiatry. 2014;45:242–251. doi: 10.1016/j.jbtep.2013.11.004.
    1. van Vreeswijk MF, Spinhoven P, Eurelings-Bontekoe EHM, Broersen J. Changes in symptom severity, schemas and modes in heterogeneous psychiatric patient groups following short-term schema cognitive-behavioural group therapy: a naturalistic pre-treatment and post-treatment design in an outpatient clinic. Clin Psychol Psychother. 2014;21:29–38. doi: 10.1002/cpp.1813.
    1. Kazdin AE. Mediators and mechanisms of change in psychotherapy research. Annu Rev Clin Psychol. 2007;3:1–27. doi: 10.1146/annurev.clinpsy.3.022806.091432.
    1. Kazdin AE. Understanding how and why psychotherapy leads to change. Psychother Res. 2009;19:418–428. doi: 10.1080/10503300802448899.
    1. Cuijpers P, Reijnders M, Huibers MJH. The role of common factors in psychotherapy outcomes. Annu Rev Clin Psychol. 2018. 10.1146/annurev-clinpsy-050718-095424.
    1. Petrik AM, Cronin TJ. Defining and measuring mechanisms of change in psychological therapies: the path not taken. Aust Psychol. 2014;49:283–286. doi: 10.1111/ap.12073.
    1. Johansson P, Høglend P. Identifying mechanisms of change in psychotherapy: mediators of treatment outcome. Clin Psychol Psychother. 2007;14:1–9. doi: 10.1002/cpp.514.
    1. Garratt G, Ingram RE, Rand KL, Sawalani G. Cognitive processes in cognitive therapy: evaluation of the mechanisms of change in the treatment of depression. Clin Psychol Sci Pract. 2007;14:224–239. doi: 10.1111/j.1468-2850.2007.00081.x.
    1. Vittengl JR, Clark LA, Thase ME, Jarrett RB. Are improvements in cognitive content and depressive symptoms correlates or mediators during acute-phase cognitive therapy for recurrent major depressive disorder? Int J Cogn Ther. 2014;7:255–271. doi: 10.1521/ijct.2014.7.3.251.
    1. Lemmens LHJM, Müller VNLS, Arntz A, Huibers MJH. Mechanisms of change in psychotherapy for depression: an empirical update and evaluation of research aimed at identifying psychological mediators. Clin Psychol Rev. 2016;50:95–107. doi: 10.1016/j.cpr.2016.09.004.
    1. Dietz LJ, Marshal MP, Burton CM, Bridge JA, Birmaher B, Kolko D, et al. Social problem solving among depressed adolescents is enhanced by structured psychotherapies. J Consult Clin Psychol. 2014;82:202–211. doi: 10.1037/a0035718.
    1. Kolko DJ, Brent DA, Baugher M, Bridge J, Birmaher B. Cognitive and family therapies for adolescent depression: treatment specificity, mediation, and moderation. J Consult Clin Psychol. 2000;68:603–614. doi: 10.1037/0022-006X.68.4.603.
    1. Renner F, DeRubeis R, Arntz A, Peeters F, Lobbestael J, Huibers MJH. Exploring mechanisms of change in schema therapy for chronic depression. J Behav Ther Exp Psychiatry. 2018;58:97–105. doi: 10.1016/j.jbtep.2017.10.002.
    1. Thimm JC. Mediation of early maladaptive schemas between perceptions of parental rearing style and personality disorder symptoms. J Behav Ther Exp Psychiatry. 2010;41:52–59. doi: 10.1016/j.jbtep.2009.10.001.
    1. Paul GL. Strategy of outcome research in psychotherapy. J Consult Psychol. 1967;31:109–118. doi: 10.1037/h0024436.
    1. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry. 2010;167:1445–1455. doi: 10.1176/appi.ajp.2010.09111680.
    1. DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L. The personalized advantage index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One. 2014;9:e83875. doi: 10.1371/journal.pone.0083875.
    1. Menchetti M, Rucci P, Bortolotti B, Bombi A, Scocco P, Kraemer HC, et al. Moderators of remission with interpersonal counselling or drug treatment in primary care patients with depression: randomised controlled trial. Br J Psychiatry. 2014;204:144–150. doi: 10.1192/bjp.bp.112.122663.
    1. Bastos AG, Guimarães LS, Trentini CM. Predictors of response in the treatment of moderate depression. Braz J Psychiatry. 2017;39:12–20. doi: 10.1590/1516-4446-2016-1976.
    1. Kappelmann N, Rein M, Fietz J, Mayberg HS, Craighead WE, Dunlop BW, et al. Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a symptom-oriented therapy (SOrT) metric for a personalised psychiatry. BMC Med. 2020;18:170. doi: 10.1186/s12916-020-01623-9.
    1. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149:734–750. doi: 10.7326/0003-4819-149-10-200811180-00008.
    1. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008;69:1287–1292. doi: 10.4088/jcp.v69n0812.
    1. Cohen ZD, Kim TT, Van HL, Dekker JJM, Driessen E. A demonstration of a multi-method variable selection approach for treatment selection: recommending cognitive-behavioral versus psychodynamic therapy for mild to moderate adult depression. Psychother Res. 2020;30:137–150. doi: 10.1080/10503307.2018.1563312.
    1. Friedl N, Berger T, Krieger T, Caspar F, Grosse HM. Using the personalized advantage index for individual treatment allocation to cognitive behavioral therapy (CBT) or a CBT with integrated exposure and emotion-focused elements (CBT-EE). Psychother Res. 2019:1–13. 10.1080/10503307.2019.1664782.
    1. Fabbri C, Hosak L, Mössner R, Giegling I, Mandelli L, Bellivier F, et al. Consensus paper of the WFSBP task force on genetics: genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J Biol Psychiatry. 2017;18:5–28. doi: 10.1080/15622975.2016.1208843.
    1. Phillips ML, Chase HW, Sheline YI, Etkin A, Almeida JRC, Deckersbach T, et al. Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry. 2015;172:124–138. doi: 10.1176/appi.ajp.2014.14010076.
    1. Kessler RC, van Loo HM, Wardenaar KJ, Bossarte RM, Brenner LA, Ebert DD, et al. Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. Epidemiol Psychiatr Sci. 2017;26:22–36. doi: 10.1017/S2045796016000020.
    1. de Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res. 2016;240:421–430. doi: 10.1016/j.psychres.2016.04.034.
    1. Cuijpers P. Personalized treatment for functional outcome in depression. Medicographia. 2014;36:476–481.
    1. Lin E, Lin C-H, Lane H-Y. Precision psychiatry applications with pharmacogenomics: artificial intelligence and machine learning approaches. Int J Mol Sci. 2020. 10.3390/ijms21030969.
    1. Dwyer DB, Falkai P, Koutsouleris N. Machine learning approaches for clinical psychology and psychiatry. Annu Rev Clin Psychol. 2018;14:91–118. doi: 10.1146/annurev-clinpsy-032816-045037.
    1. Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord. 2019;243:503–515. doi: 10.1016/j.jad.2018.09.067.
    1. Cohen ZD, DeRubeis RJ. Treatment selection in depression. Annu Rev Clin Psychol. 2018;14:209–236. doi: 10.1146/annurev-clinpsy-050817-084746.
    1. Keck ME, Kappelmann N, Kopf-Beck J. Translational research as prerequisite for personalized psychiatry. Eur Arch Psychiatry Clin Neurosci. 2018;268:215–217. doi: 10.1007/s00406-018-0885-3.
    1. Hautzinger M, Keller F, Kühner C, Beck AT. Beck-depressions-Inventar: BDI II ; revision; manual. 2nd ed. Frankfurt am Main. Frankfurt: Pearson; 2009.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. doi: 10.1192/bjp.134.4.382.
    1. Egli S, Frieß E, Graf P, Höhn D, Kopf-Beck J, Rein ML, et al. Schematherapie bei Depressionen: Ein Behandlungskonzept für das (teil) stationäre setting. 1. Göttingen: Hogrefe Verlag; 2019.
    1. Behaviour therapy and the neuroses: Readings in modern methods of treatment derived from learning theory. 3rd ed. Oxford: Pergamon Press; 1967.
    1. Beck AT. Cognitive therapy and the emotional disorders. 1976.
    1. Beck AT. Cognitive therapy of depression. 1979.
    1. S3-Leitlinien/nationale Versorgungsleitlinie unipolare Depression - Langfassung. 2nd ed.; 2015.
    1. Hautzinger M. Kognitive Verhaltenstherapie bei Depressionen: Mit online-Materialien. 7. Weinheim: Beltz; 2013.
    1. Grawe K. Grundriss einer allgemeinen Psychotherapie. Psychotherapeut. 1995;40:130–145.
    1. Frank JD. Therapeutic factors in psychotherapy. Am J Psychother. 1971;25:350–361. doi: 10.1176/appi.psychotherapy.1971.25.3.350.
    1. McCullough L, Kuhn N, Andrews S, Kaplan A, Wolf J, Hurley CL. Treating affect phobia: a manual for short-term dynamic psychotherapy. New York: Guilford Press; 2003.
    1. Greenberg LS. Emotion–focused therapy. Clin Psychol Psychother. 2004;11:3–16. doi: 10.1002/cpp.388.
    1. Schramm E, Hautzinger M, Zobel I, Kriston L, Berger M, Härter M. Comparative efficacy of the cognitive behavioral analysis system of psychotherapy versus supportive psychotherapy for early onset chronic depression: design and rationale of a multisite randomized controlled trial. BMC Psychiatry. 2011;11:134. doi: 10.1186/1471-244X-11-134.
    1. Schulte D. Messung der Therapieerwartung und Therapieevaluation von Patienten (PATHEV) Z Klin Psychol Psychother. 2005;34:176–187. doi: 10.1026/1616-3443.34.3.176.
    1. Berger M, Wolff J, Normann C, Godemann F, Schramm E, Klimke A, et al. Leitliniengerechte psychiatrisch-psychotherapeutische Krankenhausbehandlung : normative Personalermittlung am Beispiel depression. Nervenarzt. 2015;86:542–548. doi: 10.1007/s00115-015-4310-0.
    1. Bamelis LLM, Evers SMAA, Arntz A. Design of a multicentered randomized controlled trial on the clinical and cost effectiveness of schema therapy for personality disorders. BMC Public Health. 2012;12:75. doi: 10.1186/1471-2458-12-75.
    1. Guidi J, Brakemeier E-L, Bockting CLH, Cosci F, Cuijpers P, Jarrett RB, et al. Methodological recommendations for trials of psychological interventions. Psychother Psychosom. 2018;87:276–284. doi: 10.1159/000490574.
    1. Edwards BC, Lambert MJ, Moran PW, McCully T, Smith KC, Ellingson AG. A meta-analytic comparison of the Beck depression inventory and the Hamilton rating scale for depression as measures of treatment outcome. Br J Clin Psychol. 1984;23:93–99. doi: 10.1111/j.2044-8260.1984.tb00632.x.
    1. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77–100. doi: 10.1016/0272-7358(88)90050-5.
    1. Svanborg P, Åsberg M. A comparison between the Beck depression inventory (BDI) and the self-rating version of the Montgomery Åsberg depression rating scale (MADRS) J Affect Disord. 2001;64:203–216. doi: 10.1016/s0165-0327(00)00242-1.
    1. Wittchen H-U, Lachner G, Wunderlich U, Pfister H. Test-rest reliability of the computerized DSM-IV verions of the Munich-composite international diagnostic interview (M-CIDI) Soc Psychiatry Psychiatr Epidemiol. 1998;33:568–578. doi: 10.1007/s001270050095.
    1. Franke GH. Brief symptom inventory von L. R. Derogatis - deutsche version. Göttingen: Beltz; 2000.
    1. Ustun TB, Kostanjesek N, Chatterji S, Rehm J, World Health Organization . In: Measuring health and disability : manual for WHO disability assessment schedule (WHODAS 2.0) Üstün TB, Kostanjsek N, Chatterji S, Rehm J, editors. Geneva: World Health Organization; 2010.
    1. Kim S. Encyclopedia of quality of life and well-being research. Dordrecht: Springer; 2014. World Health Organization quality of life (WHOQOL) assessment; pp. 7260–7261.
    1. Schramm E, Kriston L, Zobel I, Bailer J, Wambach K, Backenstrass M, et al. Effect of disorder-specific vs nonspecific psychotherapy for chronic depression: a randomized clinical trial. JAMA Psychiat. 2017;74:233–242. doi: 10.1001/jamapsychiatry.2016.3880.
    1. Horvath AO, Greenberg LS. Development and validation of the working Alliance inventory. J Couns Psychol. 1989;36:223–233. doi: 10.1037/0022-0167.36.2.223.
    1. Louis JP, Wood AM, Lockwood G, Ho M-HR, Ferguson E. Positive clinical psychology and schema therapy (ST): the development of the Young positive schema questionnaire (YPSQ) to complement the Young schema questionnaire 3 short form (YSQ-S3) Psychol Assess. 2018;30:1199–1213. doi: 10.1037/pas0000567.
    1. Reiss N, Dominiak P, Harris D, Knörnschild C, Schouten E, Jacob GA. Reliability and validity of the German version of the schema mode inventory. Eur J Psychol Assess. 2012;28:297–304. doi: 10.1027/1015-5759/a000110.
    1. Steffanowski A, Oppl M, Meyerberg J, Schmidt J, Wittmann WW, Nübling R. Psychometrische Überprüfung einer deutschsprachigen version des relationship scales questionnaire (RSQ). In: Störungsspezifische Therapieansätze - Konzepte und Ergebnisse. p. 320–42.
    1. Appel M, Gnambs T, Maio GR. A short measure of the need for affect. J Pers Assess. 2001;94:418–26. 10.1080/00223891.2012.666921.
    1. Krohne HW, Egloff B, Kohlmann C-W, Tausch A. Untersuchungen mit einer deutschen version der "positive and negative affect schedule" (PANAS) 1996.
    1. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063–1070. doi: 10.1037/0022-3514.54.6.1063.
    1. Abler B, Kessler H. Emotion regulation questionnaire – Eine deutschsprachige Fassung des ERQ von Gross und John. Diagnostica. 2009;55:144–152. doi: 10.1026/0012-1924.55.3.144.
    1. Gross JJ, John OP. Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. J Pers Soc Psychol. 2003;85:348–362. doi: 10.1037/0022-3514.85.2.348.
    1. Hollon SD, Kendall PC. Cognitive self-statements in depression: development of an automatic thoughts questionnaire. Cogn Ther Res. 1980;4:383–395. doi: 10.1007/BF01178214.
    1. Hautzinger M, Joormann J, Keller F. DAS - Skala dysfunktionaler Einstellungen. Göttingen: Hogrefe Verlag; 2005.
    1. Huys QJM, Renz D, Petzschner F, Berwian I, Stoppel C, Haker H. German translation and validation of the cognitive style questionnaire short form (CSQ-SF-D) PLoS One. 2016;11:e0149530. doi: 10.1371/journal.pone.0149530.
    1. Kovaleva A, Beierlein C, Kemper CJ, Rammstedt B. Eine Kurzskala zur Messung von Kontrollüberzeugungen: die Skala Internale-Externale-Kontrollüberzeugung-4 (IE-4) 2012.
    1. Beierlein C, Kovaleva A, Kemper CJ, Rammstedt B. Allgemeine Selbstwirksamkeit Kurzskala ASKU - manual: Gesis. 2012.
    1. Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968;4:443–453. doi: 10.1007/BF01530764.
    1. Mander JV, Wittorf A, Schlarb A, Hautzinger M, Zipfel S, Sammet I. Change mechanisms in psychotherapy: multiperspective assessment and relation to outcome. Psychother Res. 2013;23:105–116. doi: 10.1080/10503307.2012.744111.
    1. Hartmann A, Leonhart R, Hermann S, Joos A, Stiles WB, Zeeck A. Die evaluation von Therapiesitzungen durch Patienten und Therapeuten. Diagnostica. 2013;59:45–59. doi: 10.1026/0012-1924/a000078.
    1. Gjelsvik B, Kappelmann N, von Soest T, Hinze V, Baer R, Hawton K, et al. Thought-action fusion in individuals with a history of recurrent depression and suicidal depression: findings from a community sample. Cogn Ther Res. 2018;42:782–793. doi: 10.1007/s10608-018-9924-7.
    1. Chmitorz A, Wenzel M, Stieglitz R-D, Kunzler A, Bagusat C, Helmreich I, et al. Population-based validation of a German version of the brief resilience scale. PLoS One. 2018;13:e0192761. doi: 10.1371/journal.pone.0192761.
    1. Klein EM, Brähler E, Dreier M, Reinecke L, Müller KW, Schmutzer G, et al. The German version of the perceived stress scale - psychometric characteristics in a representative German community sample. BMC Psychiatry. 2016;16:159. doi: 10.1186/s12888-016-0875-9.
    1. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–396. doi: 10.2307/2136404.
    1. Kühner C, Huffziger S, Nolen-Hoeksema S. RSQ-D: response styles questionnaire - deutsche version. Göttingen: hogrefe; 2007.
    1. Burton C, McKinstry B, Szentagotai Tătar A, Serrano-Blanco A, Pagliari C, Wolters M. Activity monitoring in patients with depression: a systematic review. J Affect Disord. 2013;145:21–28. doi: 10.1016/j.jad.2012.07.001.
    1. Schrijvers D, Hulstijn W, Sabbe BGC. Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool. J Affect Disord. 2008;109:1–20. doi: 10.1016/j.jad.2007.10.019.
    1. Morgenthaler T, Alessi C, Friedman L, Owens J, Kapur V, Boehlecke B, et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep. 2007;30:519–529. doi: 10.1093/sleep/30.4.519.
    1. Kleinbub JR. State of the art of interpersonal physiology in psychotherapy: a systematic review. Front Psychol. 2017;8:2053. doi: 10.3389/fpsyg.2017.02053.
    1. Atzil-Slonim D, Bar-Kalifa E, Fisher H, Peri T, Lutz W, Rubel J, et al. Emotional congruence between clients and therapists and its effect on treatment outcome. J Couns Psychol. 2018;65:51–64. doi: 10.1037/cou0000250.
    1. Koole SL, Tschacher W. Synchrony in psychotherapy: a review and an integrative framework for the therapeutic Alliance. Front Psychol. 2016;7:862. doi: 10.3389/fpsyg.2016.00862.
    1. Soma CS, Baucom BRW, Xiao B, Butner JE, Hilpert P, Narayanan S, et al. Coregulation of therapist and client emotion during psychotherapy. Psychother Res. 2020;30:591–603. doi: 10.1080/10503307.2019.1661541.
    1. Bar-Kalifa E, Prinz JN, Atzil-Slonim D, Rubel JA, Lutz W, Rafaeli E. Physiological synchrony and therapeutic alliance in an imagery-based treatment. J Couns Psychol. 2019;66:508–517. doi: 10.1037/cou0000358.
    1. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1–32. doi: 10.1146/annurev.clinpsy.3.022806.091415.
    1. Ehring T, Watkins ER. Repetitive negative thinking as a Transdiagnostic process. Int J Cogn Ther. 2008;1:192–205. doi: 10.1680/ijct.2008.1.3.192.
    1. Ben-Zeev D, Young MA, Madsen JW. Retrospective recall of affect in clinically depressed individuals and controls. Cognit Emot. 2009;23:1021–1040. doi: 10.1080/02699930802607937.
    1. Colombo D, Fernández-Álvarez J, Patané A, Semonella M, Kwiatkowska M, García-Palacios A, et al. Current state and future directions of technology-based ecological momentary assessment and intervention for major depressive disorder: a systematic review. J Clin Med. 2019. 10.3390/jcm8040465.
    1. Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019;15:1249–1258. doi: 10.2147/NDT.S199746.
    1. McIntyre RS, Xiao HX, Syeda K, Vinberg M, Carvalho AF, Mansur RB, et al. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 2015;29:577–589. doi: 10.1007/s40263-015-0263-x.
    1. Carter JD, McIntosh VV, Jordan J, Porter RJ, Douglas K, Frampton CM, et al. Patient predictors of response to cognitive behaviour therapy and schema therapy for depression. Aust N Z J Psychiatry. 2018;52:887–897. doi: 10.1177/0004867417750756.
    1. Murrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. 2011;96:553–563. doi: 10.1016/j.nlm.2011.06.006.
    1. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2013;139:81–132. doi: 10.1037/a0028727.
    1. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41:1165–1174. doi: 10.1017/S0033291710001911.
    1. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord. 2011;134:20–31. doi: 10.1016/j.jad.2010.11.011.
    1. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30:515–527. doi: 10.1002/da.22063.
    1. Zimmermann P, Fimm B. Applied neuropsychology of attention: theory, diagnosis, and rehabilitation. London, New York: Psychology Press; 2002. A test battery of attentional performance; pp. 110–151.
    1. Balzer C, Berger J-M, Caprez G, Gonser A, Gutbrod K, Keller M. Materialien und Normwerte für die neuropsychologische Diagnostik: MNND. Rheinfelden: Normdaten; 2011.
    1. Brickenkamp R, Schmidt-Atzert L, Liepmann D. d2-R: test d2 - revision. Göttingen: hogrefe; 2010.
    1. Lehrl S. Mehrfachwahl-Wortschaty-Intelligenztest: MWT-B. 5. Balingen: Spitta; 2005.
    1. Beauchaine TP, Thayer JF. Heart rate variability as a transdiagnostic biomarker of psychopathology. Int J Psychophysiol. 2015;98:338–350. doi: 10.1016/j.ijpsycho.2015.08.004.
    1. Schiweck C, Piette D, Berckmans D, Claes S, Vrieze E. Heart rate and high frequency heart rate variability during stress as biomarker for clinical depression. A systematic review. Psychol Med. 2019;49:200–211. doi: 10.1017/S0033291718001988.
    1. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67:1067–1074. doi: 10.1016/j.biopsych.2009.12.012.
    1. Schumann G, Binder EB, Holte A, de Kloet ER, Oedegaard KJ, Robbins TW, et al. Stratified medicine for mental disorders. Eur Neuropsychopharmacol. 2014;24:5–50. doi: 10.1016/j.euroneuro.2013.09.010.
    1. Coleman JRI, Gaspar HA, Bryois J, Breen G. The genetics of the mood disorder Spectrum: genome-wide association analyses of more than 185,000 cases and 439,000 controls. Biol Psychiatry. 2020;88:169–184. doi: 10.1016/j.biopsych.2019.10.015.
    1. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–681. doi: 10.1038/s41588-018-0090-3.
    1. Penner-Goeke S, Binder EB. Epigenetics and depression. Dialogues Clin Neurosci. 2019;21:397–405. doi: 10.31887/DCNS.2019.21.4/ebinder.
    1. Coleman JRI, Peyrot WJ, Purves KL, Davis KAS, Rayner C, Choi SW, et al. Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK biobank. Mol Psychiatry. 2020;25:1430–1446. doi: 10.1038/s41380-019-0546-6.
    1. Jiménez JP, Botto A, Herrera L, Leighton C, Rossi JL, Quevedo Y, et al. Psychotherapy and genetic neuroscience: an emerging dialog. Front Genet. 2018;9:257. doi: 10.3389/fgene.2018.00257.
    1. Brückl TM, Spoormaker VI, Sämann PG, Brem A-K, Henco L, Czamara D, et al. The biological classification of mental disorders (BeCOME) study: a protocol for an observational deep-phenotyping study for the identification of biological subtypes. BMC Psychiatry. 2020;20:213. doi: 10.1186/s12888-020-02541-z.
    1. Rigucci S, Serafini G, Pompili M, Kotzalidis GD, Tatarelli R. Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies. World J Biol Psychiatry. 2010;11:165–180. doi: 10.1080/15622970903131571.
    1. Schmaal L, Pozzi E, C Ho T, van Velzen LS, Veer IM, Opel N, et al. ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing. Transl Psychiatry. 2020;10:172. doi: 10.1038/s41398-020-0842-6.
    1. Marwood L, Wise T, Perkins AM, Cleare AJ. Meta-analyses of the neural mechanisms and predictors of response to psychotherapy in depression and anxiety. Neurosci Biobehav Rev. 2018;95:61–72. doi: 10.1016/j.neubiorev.2018.09.022.
    1. Schilbach L, Wilms M, Eickhoff SB, Romanzetti S, Tepest R, Bente G, et al. Minds made for sharing: initiating joint attention recruits reward-related neurocircuitry. J Cogn Neurosci. 2010;22:2702–2715. doi: 10.1162/jocn.2009.21401.
    1. Brandi M-L, Kaifel D, Bolis D, Schilbach L. The interactive self – a review on simulating social interactions to understand the mechanisms of social agency. i-com. 2019;18:17–31. doi: 10.1515/icom-2018-0018.
    1. Mathys CD, Lomakina EI, Daunizeau J, Iglesias S, Brodersen KH, Friston KJ, et al. Uncertainty in perception and the hierarchical Gaussian filter. Front Hum Neurosci. 2014. 10.3389/fnhum.2014.00825.
    1. Sevgi M, Diaconescu AO, Henco L, Tittgemeyer M, Schilbach L. Social Bayes: using Bayesian modeling to study autistic trait-related differences in social cognition. Biol Psychiatry. 2020;87:185–193. doi: 10.1016/j.biopsych.2019.09.032.
    1. Bandura A. Social learning theory. New York: General Learning Press; 1977.
    1. Browning M, Behrens TE, Jocham G, O'Reilly JX, Bishop SJ. Anxious individuals have difficulty learning the causal statistics of aversive environments. Nat Neurosci. 2015;18:590–596. doi: 10.1038/nn.3961.
    1. Jain FA, Hunter AM, Brooks JO, Leuchter AF. Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress Anxiety. 2013;30:624–630. doi: 10.1002/da.22045.
    1. Riedel M, Möller H-J, Obermeier M, Adli M, Bauer M, Kronmüller K, et al. Clinical predictors of response and remission in inpatients with depressive syndromes. J Affect Disord. 2011;133:137–149. doi: 10.1016/j.jad.2011.04.007.
    1. Cuijpers P, Ebert DD, Acarturk C, Andersson G, Cristea IA. Personalized psychotherapy for adult depression: a meta-analytic review. Behav Ther. 2016;47:966–980. doi: 10.1016/j.beth.2016.04.007.
    1. Doering S, Renn D, Höfer S, Rumpold G, Smrekar U, Janecke N, et al. Validierung der deutschen version des Fragebogens zur Erfassung von DSM-IV Persönlichkeitsstorungen (ADP-IV) Z Psychosom Med Psychother. 2007;53:111–128. doi: 10.13109/zptm.2007.53.2.111.
    1. Morey LC. Development and initial evaluation of a self-report form of the DSM-5 level of personality functioning scale. Psychol Assess. 2017;29:1302–1308. doi: 10.1037/pas0000450.
    1. Markon KE, Quilty LC, Bagby RM, Krueger RF. The development and psychometric properties of an informant-report form of the personality inventory for DSM-5 (PID-5) Assessment. 2013;20:370–383. doi: 10.1177/1073191113486513.
    1. Zimmermann J, Altenstein D, Krieger T, Holtforth MG, Pretsch J, Alexopoulos J, et al. The structure and correlates of self-reported DSM-5 maladaptive personality traits: findings from two German-speaking samples. J Pers Disord. 2014;28:518–540. doi: 10.1521/pedi_2014_28_130.
    1. Zimmermann J, Böhnke JR, Eschstruth R, Mathews A, Wenzel K, Leising D. The latent structure of personality functioning: investigating criterion a from the alternative model for personality disorders in DSM-5. J Abnorm Psychol. 2015;124:532–548. doi: 10.1037/abn0000059.
    1. Bernstein DP, Fink L. Childhood trauma questionnaire: a retrospective self-report manual. San Antonio: The Psychological Corporation; 1998.
    1. Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Res. 1967;11:213–218. doi: 10.1016/0022-3999(67)90010-4.
    1. Strobel A, Beauducel A, Debener S, Brocke B. Eine deutschsprachige version des BIS/BAS-Fragebogens von carver und White. Zeitschrift für Differentielle und Diagnostische Psychologie. 2001;22:216–227. doi: 10.1024//0170-1789.22.3.216.
    1. Button KS, Kounali D, Thomas L, Wiles NJ, Peters TJ, Welton NJ, et al. Minimal clinically important difference on the Beck depression inventory--II according to the patient's perspective. Psychol Med. 2015;45:3269–3279. doi: 10.1017/S0033291715001270.
    1. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
    1. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health. 1996;86:726–728. doi: 10.2105/ajph.86.5.726.
    1. O'Connell NS, Dai L, Jiang Y, Speiser JL, Ward R, Wei W, et al. Methods for analysis of pre-post data in clinical research: a comparison of five common methods. J Biom Biostat. 2017;8:1–8. doi: 10.4172/2155-6180.1000334.
    1. Chu R, Thabane L, Ma J, Holbrook A, Pullenayegum E, Devereaux PJ. Comparing methods to estimate treatment effects on a continuous outcome in multicentre randomized controlled trials: a simulation study. BMC Med Res Methodol. 2011;11:21. doi: 10.1186/1471-2288-11-21.
    1. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi: 10.1136/bmj.b2393.
    1. Preacher KJ, Zhang Z, Zyphur MJ. Alternative methods for assessing mediation in multilevel data: the advantages of multilevel SEM. Struct Equ Modeling. 2011;18:161–182. doi: 10.1080/10705511.2011.557329.
    1. Curran PJ, Bauer DJ. The disaggregation of within-person and between-person effects in longitudinal models of change. Annu Rev Psychol. 2011;62:583–619. doi: 10.1146/annurev.psych.093008.100356.
    1. Preacher KJ, Zyphur MJ, Zhang Z. A general multilevel SEM framework for assessing multilevel mediation. Psychol Methods. 2010;15:209–233. doi: 10.1037/a0020141.
    1. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world mental health surveys. JAMA. 2004;291:2581–2590. doi: 10.1001/jama.291.21.2581.
    1. Grant BF, Hasin DS, Stinson FS, Dawson DA, Patricia Chou S, June Ruan W, et al. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions. J Psychiatr Res. 2005;39:1–9. doi: 10.1016/j.jpsychires.2004.05.004.
    1. Gunderson JG, Stout RL, Sanislow CA, Shea MT, McGlashan TH, Zanarini MC, et al. New episodes and new onsets of major depression in borderline and other personality disorders. J Affect Disord. 2008;111:40–45. doi: 10.1016/j.jad.2008.01.026.
    1. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:698–702. doi: 10.1136/bmj.c332.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner